2 articles · Updated · Inside Precision Medicine · Jun 18
Summary
Yale researchers reported in Science Immunology that a two-step HSV-2 vaccine strategy improved protective mucosal immunity in mice by pairing intramuscular priming with an intravaginal BEACONs booster.
The booster combined CpG oligodeoxynucleotides with the chemokine CXCL9, which increased uptake by antigen-presenting cells and recruited HSV-specific CD8 tissue-resident memory T cells to vaginal mucosa.
That effect appeared only with the full local combination treatment; CXCL9 alone, CpG ODNs alone, intramuscular boosting, CXCL10, and a truncated CXCL9 variant did not produce the same durable response.
The approach aims to solve a central HSV-2 vaccine problem: vaginal mucosal immunosuppression blunts immune priming, while earlier intravaginal CpG delivery could lower viral loads but often triggered substantial inflammation.
The team said the nanoparticle platform could be adapted for other sexually transmitted infections including HIV-1, HPV and chlamydia, though longer-term shedding data, alternate models and delivery options still need testing.
Could a new vaccine tame genital herpes without triggering the chronic inflammation that plagues other immune therapies?
If this vaccine works for herpes, could it finally defeat notoriously evasive STIs like HIV or gonorrhea?
New BEACONs Vaccine Strategy Shows High Efficacy Against Genital Herpes in Mice, Paving Way for Human Trials
Overview
Yale University has developed a promising new HSV-2 vaccine using the BEACONs strategy, which combines immune-stimulating DNA and the chemokine CXCL9 in specially engineered nanoparticles. This approach uses a 'prime and pull' method: first, an intramuscular mRNA vaccine primes the immune system, then a mucosal boost delivers the BEACONs nanoparticles with HSV-2 glycoproteins directly to the vaginal mucosa. This targeted delivery recruits immune cells and enhances local mucosal immunity, which is essential for preventing sexually transmitted infections like HSV-2. Early studies show this method could overcome past vaccine challenges by providing strong, localized protection.